Trials / Completed
CompletedNCT04049474
Bronchoscopic Cryo-Immunotherapy of Lung Cancer
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 22 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and feasibility study of bronchoscopic cryo-immunotherapy (BCI) of peripheral lung tumors in advanced non-small cell lung cancer for the intention of inducing anti-tumor immune responses. The sample size for this study will be 15 patients. Pre- and post- BCI peripheral blood samples will be analyzed to assess for anti-tumor immune responses. Post-BCI peripheral blood will be collected 7 and 14 days after the procedure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany) | See BCI description. |
Timeline
- Start date
- 2020-02-15
- Primary completion
- 2024-04-09
- Completion
- 2024-04-09
- First posted
- 2019-08-08
- Last updated
- 2025-04-24
- Results posted
- 2025-04-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04049474. Inclusion in this directory is not an endorsement.